In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue

European Urology

Volumn 42, Issue 5, 2002, Pages 523-528

  Seidler, Michael ^a   Ückert, Stefan ^a   Waldkirch, Eginhard ^a   Stief, Christian G ^a   Oelke, Matthias ^a   Tsikas, Dimitrios ^a   Sohn, Michael ^b   Jonas, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

CGMP; Human corpus cavernosum; Nitric oxide donors; S nitrosothiols

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC GMP; NCX 091; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; S NITROSO N ACETYLCYSTEINE ETHYL ESTER; S NITROSOGLUTATHIONE; SILDENAFIL; SILDENAFIL NITRATE; TETRODOTOXIN; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; ADULT; EVALUATION; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; PENIS; PENIS ERECTION; PHYSIOLOGY;

ADULT; CYCLIC GMP; ELECTRIC STIMULATION; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; PENILE ERECTION; PENIS; PIPERAZINES;

EID: 0036853865     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00397-4     Document Type: Article

References (27)

1. Andersson K-E, Wagner G. Physiology of penile erection. Pharmacol Rev 1995;75:191-236.
2. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404.
3. Patma-Nathan H, McMurray J, Saoud J, Ferguson K, Dullman W, Whitaker S, Rosen R. On-demand treatment of erectile dysfunction with IC 351. Eur Urol 2000;37(Suppl 2):80.
4. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: A RigiScan and pharmacokinetic study. World J Urol 2001;19:32-9.
5. Schmidt K, Schrammel A, Koesling D, Mayer B. Molecular mechanisms involved in synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Mol Pharmacol 2001:59:220-4.
6. Heaton JP, Morales A, Owen J. Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. J Urol 1990; 143:729-31.
7. Truss MC, Becker AJ, Schultheiss D, Jonas U. Intracavernous pharmacotherapy. World J Urol 1997;15:71-7.
8. Kandeel FR, Koussa VKT, Swerdloff RS. Male sexual function and its disorders: Physiology, pathophysiology, clinical investigation, and treatment. Endocrine Rev 2001;22:342-88.
9. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurological basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther 2001;296:225-34.
10. Al-Sa'doni HH, Khan IY, Poston L, Fisher I, Ferro A. A novel family of S-nitrosothiols: Chemical synthesis and biological actions. Nitric Oxide 2000;4:550-60.
11. 2 synthesis in human blood platelets. FEBS Lett 1999;442:162-6.
12. Zorgniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor L-arginine on erectile dysfunction. Int J Impot Res 1994; 6:33-5.
13. Truss MC, Becker AJ, Djamillian MH, Stief CG, Jonas U. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 1994;44: 553-6.
14. Rotella DP, Sun Z, Zhu Y, Krupinski J, Pongrac R, Seliger L, Normandin D, Macor JE. N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. J Med Chem 2000;43:1257-63.
15. Yildirim S, Simsek R, Ayan S, Gökce G, Sarioglu Y, Safak C. Relaxant effects of some benzothiazolinone derivates on isolated rabbit corpus cavernosum. Urol Res 2001;29:182-5.
16. Butler AR, Rhodes P, Chemistry, analysis, and biological roles of S-nitrosothiols. Anal Biochem 1997;249:1-9.
17. Wallace JL, Reuter BK, Cirino G. Nitric oxide releasing non-steroidal anti-inflammatory drugs: A novel approach for reducing gastrointestinal toxicity. J Gastroenterol Hepatol 1994; 9:S40-4.
18. Marotto S, Menegazzi M, Carcereri de Prati A, Cuzzolin L, Adami A, Suzuki H, Benoni G. Protective effect of NO on gastric lessions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivative, nitroflurbiprofen. Br J Pharmacol 1995; 116:1713-4.
19. Toward TJ, Lewis-Lakelin MB, Burgaud JL, Broadley KJ. 2001. Comparison of the inhibition by NO-salbutamol and salbutamol of the bronchoconstriction by histamine in concious guinea-pigs. In: Proceedings of the Fifthth World Congress on Inflammation, Edinburgh, Scotland, 22.09.-26.09.2001, Congress Abstracts Volume: S181, Abstract W19/01.
20. Wallace JL, Muscara MN, McKnight W, Dicay M, De Soldato P, Cirino G. In vivo anti-thrombotic effects of a NO-releasing aspirin derivate, NCX 4016. Thrombosis Res 1999;93:43-50.
21. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: Relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000;279:412-9.
22. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type 5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum. Br J Urol 1997;79:958-63.
23. Chuang AT, Strauss JD, Murphy RA, Steers WD. Sildenafil, a type 5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 1998;160:257-61.
24. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977;3:23-35.
25. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999;161:5-11.
26. de Belder AJ, MacAllister R, Radomski MW, Moncada S, Vallance PJT. Effects of S-nitroso-glutathione in the human forearm circulation: Evidence for selective inhibition of platelet activation. Cardiovasc Res 1994;28:691-4.
27. Buyukafsar K, Gocmen C, Secilmis A, Karatas Y, Gokturk S, Kalyoncu NI. Evidence that nitrergic neurotransmitter and endothelium-derived relaxing factor might be S-nitrosothiols in the mouse corpus cavernosum. Acta Med Okayama 1999;53:209-15.